Invenra, a Madison startup on a cancer-fighting mission, is boosting its treasury by $3.1 million.
The money, from more than two dozen investors, according to documents filed with federal regulators, is part of a $6 million round the company plans to raise, co-founder and CEO Roland Green said.
He said previous investors who participated in the first part of the funding and a new investor will fill out the round.
"The money will allow us to continue developing our immuno-oncology drugs," Green said.
Invenra has developed a portfolio of antibodies and is working on early tests of drugs to treat skin and brain cancers, with future plans to develop potential drugs for fighting other types of cancer.
In July, Invenra announced a collaboration with Merck, one of the world's pharmaceutical giants, to find the best antibodies to treat "an unnamed target."
The company, at 505 S. Rosa Road, has 20 employees and had raised $11 million before the current round.